Pharma BD Deal Intelligence
The Monarch platform worked, the deal terms didn't: J&J's $3.4B-cash Auris buy delivered an FDA-cleared robotic bronchoscopy system, but a Delaware court found J&J committed fraud on the up-to-$2.35B earnout, awarding sellers over $1B before the Supreme Court partially reversed one milestone in January 2026.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →TechCrunch framed the deal as J&J spending heavily for an 'already-approved' lung cancer diagnostics platform, positioning it among the largest VC-backed…
A Delaware Chancery judge ordered J&J to pay former Auris shareholders more than $1B, finding J&J breached its commercially-reasonable-efforts obligations and…
Delaware Supreme Court (Jan 2026) in J&J v. Fortis Advisors affirmed the fraud finding and breach of contract on most Auris contingent-milestone earnouts, but…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Ethicon (a J&J subsidiary) agreed to acquire Auris Health for approximately $3.4B in cash plus up to $2.35B in contingent milestone payments. Auris's lead platform was the FDA-cleared Monarch robotic bronchoscopy system for lung cancer diagnosis. Acquisition closed April 1, 2019. Post-close, the up-to-$2.35B contingent earnout became the subject of major litigation: in J&J v. Fortis Advisors (Delaware), a Sept 2024 Chancery judgment awarded former Auris shareholders more than $1B, finding J&J committed fraud and breached commercially-reasonable-efforts obligations on the milestone payments; the Delaware Supreme Court (Jan 2026) affirmed the fraud finding and breach on most milestones while reversing the Milestone 1 (lung ablation 510(k)) damages and remanding for interest recalculation. The Monarch platform itself advanced under J&J with FDA 510(k) clearance of the AI-enabled MONARCH QUEST in March 2025 and publication of the 679-patient TARGET study in CHEST in May 2025.
Assessment window: 5yr post-close.
235K US cases/yr
Lung cancer remains the leading cause of cancer death in the US, with most patients diagnosed at advanced stage when curative-intent surgery is no longer feasible. Robotic-assisted bronchoscopy (RAB) platforms enable minimally invasive biopsy of small, peripheral pulmonary nodules detected by low-dose CT screening, addressing a clinical gap where conventional bronchoscopy and CT-guided needle biopsy have meaningful diagnostic-yield and pneumothorax-risk tradeoffs.
At deal close (April 2019) Auris's Monarch (FDA-cleared March 2018) was the first-mover RAB platform, using electromagnetic navigation (EMN) and an articulating outer/inner sheath design (PMC review, https://pmc.ncbi.nlm.nih.gov/articles/PMC9962823/). Its head-to-head competitor was Intuitive Surgical's Ion Endoluminal System, which received FDA clearance in February 2019 and shipped in Q2 2019 using shape-sensing fiber-optic technology (TheRobotReport, https://www.therobotreport.com/ion-lung-biopsy-intuitive-surgical-fda/). Legacy navigation-bronchoscopy platforms from Medtronic (superDimension/iLogic) and Veran Medical (SPiN, later acquired by Olympus) competed in adjacent segments. SVB Leerink analysts called the J&J–Auris deal 'a positive on the margin' for J&J's robotics commitment (FierceBiotech, https://www.fiercebiotech.com/medtech/jj-ordered-pay-1b-over-fallout-auris-robotic-surgery-deal). Strategically, J&J framed Monarch as the foundation of its Lung Cancer Initiative, complementing the Verb Surgical (later Ottava) soft-tissue robotic platform and the orthopedics-focused VELYS — a multi-modality robotics roadmap to challenge Intuitive's daVinci dominance. Subsequent litigation ($1B jury verdict 2024) and Monarch product execution challenges have tempered the original deal narrative.
J&J MedTech secured U.S. 510(k) clearance for MONARCH QUEST, the AI-enabled next-gen navigation upgrade to the acquired Auris Monarch robotic-assisted bronchoscopy platform; TARGET study (679 pts) subsequently published in CHEST (May 2025) showed >98% nodule reach.
After a Sept 2024 Chancery judgment of ~$1B+ for former Auris shareholders, the Delaware Supreme Court (Jan 2026) affirmed the fraud finding and breach on most contingent-milestone earnouts but reversed the Milestone 1 (lung ablation 510(k) pathway) damages and remanded for interest recalculation — a material epilogue to the deal's up-to-$2.35B contingent structure.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Auris Health, Inc. (this deal) | 2019 | $5.8B | — |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2019 deals · Johnson & Johnson deals · Oncology deals